<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403569</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUMCH record JS-985</org_study_id>
    <nct_id>NCT03403569</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection</brief_title>
  <official_title>Impact of Triptolide Wilfordii on Viral Suppression, Immune Recovery and Immune Activation Biomarkers in Treatment-naive HIV-1 Infection: a Randomized, Double-blinded, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The traditional Chinese herbal medicine Triptolide Wilfordii has displayed remarkable effect
      on the treatment of autoimmune diseases such as rheumatoid arthritis. Now that
      immunosuppression therapy has recently become a new strategy for HIV infection, it's
      reasonable to expect the anti-inflammatory effect of Triptolide Wilfordii in HIV infected
      patients. So we designed a randomized, double-blinded, placebo-controlled study to explore
      the efficacy and safety of Triptolide Wilfordii in new-onset HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acquired immune deficiency syndrome(AIDS) is a severe fatal disease caused by HIV infection.
      Despite viral suppression achieved, antiretroviral therapy(ART) cannot ameliorate HIV-induced
      immune activation and the consequent non-AIDS complications including cardiovascular, renal,
      hepatic diseases. Recently, immunosuppression therapy has become the focus since it can
      suppress exorbitant immune activation and inflammation so as to reduce the risk of non-AIDS
      cardiovascular and central neural system complications. Triptolide Wilfordii is a traditional
      Chinese herbal remedy and has long been used in the treatment of autoimmune diseases such as
      rheumatoid arthritis. Moreover, a recent study has shown that Triptolide Wilfordii combined
      with ART is associated with increased CD4 T cell counts and reduced immune activation in
      immunological non-responders, who were defined as patients with CD4 cell counts＜350 cells/μl
      despite over 2 years of ART. Hence we expect Triptolide Wilfordii to bring up similar
      improvement in treatment naïve HIV infection. This randomized, double-blinded,
      placebo-controlled study is designed to investigate the safety and efficacy of Triptolide
      Wilfordii and hopefully provide evidence for a new treatment strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 T cell counts and HIV RNA</measure>
    <time_frame>Baseline, Week4, Week12, Week24, Week36, Week 48</time_frame>
    <description>Compared to patients in placebo group, CD4 T cells of patients treated with Triptolide Wilfordii significantly increase and HIV RNA is reduced below 20 copies/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune activation</measure>
    <time_frame>Baseline, Week4, Week12, Week24, Week36, Week 48</time_frame>
    <description>Compared to patients in placebo group, immune activation index of patients treated with Triptolide Wilfordii decreases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation level</measure>
    <time_frame>Baseline, Week4, Week12, Week24, Week36, Week 48</time_frame>
    <description>Compared to patients in placebo group, inflammation level of patients treated with Triptolide Wilfordii decreases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV reservoir</measure>
    <time_frame>Baseline, Week4, Week12, Week24, Week36, Week 48</time_frame>
    <description>Compared to patients in placebo group, HIV reservoir of patients treated with Triptolide Wilfordii is reduced.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HIV-infection/AIDS</condition>
  <arm_group>
    <arm_group_label>Triptolide Wilfordii Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptolide Wilfordii</intervention_name>
    <description>In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.</description>
    <arm_group_label>Triptolide Wilfordii Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.</description>
    <arm_group_label>Placebo Oral Tablet Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18~65 years old;

          -  Male or female;

          -  Good adherence and promise to follow-up;

          -  Inform Consent signed;

          -  Positive for HIV antibody test or serum HIV-RNA positive for 2 times or more;

        Exclusion Criteria:

          -  Present opportunity infection defined according to national AIDS treatment guideline
             or active opportunistic infection(not stable within 14 days ) within 3 months before
             recruitment or AIDS-related carcinoma;

          -  Hemoglobin (HGB) &lt; 9 g/dl, white blood cell (WBC) &lt; 3000/ul, granulin (GRN) &lt; 1500
             /ul, platelet (PLT) &lt; 75000 /ul, Cr &gt;1.5x upper limit of normal (ULN), ALT or AST or
             alkaline phosphatase (ALP) &gt;3x ULN, total bilirubin (TBIL) &gt;2x ULN;

          -  Pregnancy or breastfeeding;

          -  Woman with pregnancy plan;

          -  Severe organ dysfunction;

          -  Administration of immunosuppressor, immunomodulator(including thymocin) or systemic
             cytotoxic drugs within 6 months before recruitment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Lyu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, PekingUMCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Lyu</last_name>
    <phone>+8613501385800</phone>
    <email>lvweipumch@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhang</last_name>
    <phone>+8613207572893</phone>
    <email>zhangqingpumch@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mengchao Hepatobiliary Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HANHUI YE</last_name>
      <phone>+8613705059313</phone>
      <email>yehanhui@163.com</email>
    </contact>
    <investigator>
      <last_name>HANHUI YE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eighth People's Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HAOLAN HE</last_name>
      <phone>+8618988808877</phone>
      <email>gz8hhhl@126.com</email>
    </contact>
    <investigator>
      <last_name>HAOLAN HE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XIAOHONG CHEN</last_name>
      <phone>+8615304519158</phone>
      <email>catherine89034@163.com</email>
    </contact>
    <investigator>
      <last_name>XIAOHONG CHEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XIAOXIA YANG</last_name>
      <phone>+8613683801446</phone>
      <email>6688598@qq.com</email>
    </contact>
    <investigator>
      <last_name>XIAOXIA YANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xixi Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JIANHUA YU</last_name>
      <phone>+8613588078478</phone>
      <email>yujhmc@126.com</email>
    </contact>
    <investigator>
      <last_name>JIANHUA YU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LIJUN SUN</last_name>
      <phone>+8613161828826</phone>
      <email>sunlijun@163.com</email>
    </contact>
    <investigator>
      <last_name>LIJUN SUN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WENHUI LUN</last_name>
      <phone>+8613366126939</phone>
      <email>lunwenhui@163.com</email>
    </contact>
    <investigator>
      <last_name>WENHUI LUN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD4 cell recovery</keyword>
  <keyword>immune activation</keyword>
  <keyword>anti-inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

